Abstract: Absorbent articles are provided that comprise shaped, soft and textured nonwoven fabrics. The nonwoven fabrics may be a topsheet and an outer cover nonwoven material of the absorbent article. A portion of a wearer-facing surface of the topsheet may have a TS7 in the range of about 1 dB V2 rms of about 1 to about 4.5 dB V2 rms and a TS750 in the range of about 6 dB V2 rms to about 30 dB V2 rms. A portion of a garment-facing surface of the outer cover nonwoven material may have a TS7 in the range of about 1 dB V2 rms of about 1 to about 4.5 dB V2 rms and a TS750 in the range of about 6 dB V2 rms to about 30 dB V2 rms. The nonwoven fabrics of the present disclosure provide soft materials with texture.

Abstract: A wound dressing apparatus includes a wound dressing member dimensioned for positioning relative to a wound bed. The wound dressing member including an internal vacuum reservoir and has a port in communication with the vacuum reservoir for applying subatmospheric pressure to the vacuum reservoir to facilitate removal of fluid from the wound bed. The wound dressing member includes a visual pressure indicator associated therewith for indicating a level of pressure within the vacuum reservoir. The visual pressure indicator includes color indicia having a plurality of colors corresponding to a condition of the pressure within the vacuum reservoir. The wound dressing member includes a lower absorbent member positionable adjacent the wound bed and an upper member which at least partially defines the vacuum reservoir. At least one of the top member and the lower absorbent member has the visual pressure indicator mounted thereto.

Abstract: Embodiments of negative pressure wound therapy systems and methods are disclosed. In one embodiment, an apparatus includes a wound dressing, negative pressure source, user interface, sensor, and control circuitry. The user interface can receive an activation input. The sensor can detect whether the wound dressing is positioned over a wound. The control circuitry can cause supply of negative pressure in response to receipt of the activation input and a determination that the sensor detects that the wound dressing is positioned over the wound. In addition, the control circuitry can prevent supply of negative pressure in response to a determination that the sensor does not detect that the wound dressing is positioned over the wound.

Abstract: An external male catheter comprising an inner drainage sheath configured to unrolled and fitted over a penis like a condom, and an attached outer suction sheath configured to be unrolled over the fitted drainage sheath. A one-way drainage port extends from the inner drainage sheath through the outer suction sheath in fluid-tight manner, and a one-way suction port extends from the outer suction sheath. Suction is selectively applied to both the drainage and suction ports as the catheter is applied, in order to assist with fitting and retention of the catheter.

Abstract: An occlusion clearing device for a patient has a housing with a motor(s) that generates repetitive motion, which is reciprocating, rotational or both. A clearing stem including a sheath that has a lumen, wherein aspiration is conducted through the sheath lumen. A wire is located in the sheath lumen and receives repetitive motion from the controller. The sheath terminates in a sheath end having at least one sheath opening. The wire terminates in a wire tip, which may be flat, helical, or tubular. The wire tip is positioned within the sheath end, in proximity to the sheath opening(s), and movement of the wire tip and/or sheath end relative to each other creates shearing forces that break up an adjacent occlusion.

Abstract: A post-partum undergarment system including a brief having a pad and a compression member with a first-wing and a second-wing. The pad is integral to the brief and disposed on an inner layer of the brief in an interspace between the leg holes. The first-wing and the second-wing are configured to wrap around an abdominal region of a woman and secure the compression member in a wrapped-condition. The compression member causes direct compression to the abdominal region of the woman when the brief is worn. The brief is absorbent and disposable for use in postpartum stages.

Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.

Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.

Abstract: Disclosed are novel prenylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced in vitro or in vivo using a biosynthetic system which comprises cells comprising a prenyl transferase, and, optionally, additional enzymes, including a decarboxylase, and an N-acetyl transferase.

Abstract: In some illustrative examples, a conduit interface may include a mounting surface and an exterior-facing surface positioned across from the mounting surface, an internal cavity, an inlet port, a vent, and a temporary plug. The internal cavity may include an opening positioned proximate to the mounting surface. The inlet port may be in in fluid communication with the internal cavity through the exterior-facing surface. The vent may be in fluid communication with the internal cavity through the exterior-facing surface. The temporary plug may be configured to temporarily preclude fluid communication through the vent. The conduit interface may be suitable for providing fluid communication with a dressing at a tissue site. Also provided are other examples, apparatus, systems, and methods.

Abstract: Systems, apparatuses, and methods for providing negative pressure to a tissue site are disclosed. Illustrative embodiments may include an apparatus or system for delivering negative-pressure to a tissue site, which can be used in conjunction with low-profile distribution components for wound therapy. Such apparatus may include a low-profile dressing interface or connector comprising at least two fluid pathways fluidly coupled to a recessed space of the connector, one for providing negative pressure to a tissue interface or manifold and the other for sensing the negative pressure within the recessed space adjacent the tissue interface. In some embodiments, a pressure-offloading layer may be disposed against at least one of the fluid pathways.

Abstract: An implantable amina cribrosa crossing pressure balance maintainer for constantly balancing the lamina cribrosa crossing pressure difference, an implantation device, and a method for balancing the lamina cribrosa crossing pressure difference. The lamina cribrosa crossing pressure balance maintainer is placed at the lamina cribrosa to balance the lamina cribrosa crossing pressure difference so as to enable the deformed lamina cribrosa to recover or even reverse deformation, so that the tolerance of glaucoma patients to intraocular hypertension is improved, nerve damage caused by the lamina cribrosa crossing pressure difference is relieved and reduced, and primary factors of the glaucoma optic nerve damage are eliminated. New ideas are provided for the treatment of the glaucoma in the middle and advanced periods.

Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Abstract: A device comprising a housing having a handle end and a treatment end. The treatment end is configured to provide an antimicrobial treatment and a heat treatment. The treatment end comprises an applicator having an applicator surface for providing at least the heat treatment. The device includes a heat generation unit configured to heat the applicator surface in use, a source of antimicrobial agent, and a control unit operatively connected to at least the heat generation unit for controlling the heat generation unit. The device can be a hand-held device and used to apply topical treatment to a treatment area of a subject.

Abstract: A bodily fluid drainage assembly can include a fluid bag and one or more covers. The assembly can include one or more volume indicators from which an approximate volume of a bodily fluid that is retained within the be can be ascertained. In some arrangements, a cover includes a volume indicator that defines an opening through which a transparent or semitransparent portion of the bag can be viewed.

Abstract: Embodiments disclosed herein are directed to negative pressure treatment systems and wound dressing systems, apparatuses, and methods that may be used for the treatment of wounds. In particular, some embodiments are directed to improved wound dressings comprising an obscuring layer that may hide fluid contained therein. Some embodiments may further comprise one or more viewing windows disposed therethrough so as to enable monitoring or examination of fluids contained therein.

Abstract: The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

Abstract: Provided herein are small molecules that bind to GAS41 and inhibit GAS41 activity, and methods of use thereof for the treatment of cancer.

Abstract: Novel tetracyclic aza-podophyllotoxin analogue compounds, a method of synthesizing such compounds, a pharmaceutical composition comprising such compounds and a suitable carrier, and a method of using the compounds. The tetracyclic aza-podophyllotoxin analogue compounds are useful as antitumor agents.

Abstract: A disposable article includes a topsheet, a backsheet, and an absorbent core disposed between the topsheet and backsheet; and an elasticized waist gasketing element. The elasticized waist gasketing element has a lateral outboard edge and a longitudinal array of elastic members. The longitudinal array includes a primary waist elastic member disposed inboard of the waist edge by a minimum longitudinal distance A, a secondary waist elastic member disposed inboard of the primary waist elastic member by a minimum longitudinal distance B. The waist gasketing element comprises a Force Ratio of at least about 1.1.